Choose smart money in health
4 reasons to raise funds with Angels Santé
Access our 150+ expert healthcare investors
Connect to our French and European healthcare ecosystem
Get active support throughout your business development
Connect to our French and European healthcare ecosystem
Become an exclusive member of the Angels Santé Family
How to be selected ?
- You are a French healthcare start-up (medtech, biotech, diagnostics, e-health, animal health...).
- You are raising tour de seed de minimum 400 K€
- Votre équipe est pluridisciplinaire et complémentaire.
- Your closing date is at least 6 months away.
- You have at least one POC (proof of concept).
- Depending on your sector
- Biotech : your PoC is at the regulatory preclinical stage (in vivo PoC completed)
- Medtech : votre prototype est fonctionnel et idéalement vos premières études pilotes réalisées sur quelques patients
- Digital Health: votre solution est développée et présente un début de traction (commerciale, pilote, partenariat)
Tick all the boxes ?
Let's check your eligibility.
N.B Le dépôt de candidature est clos pour la période estivale. Nous ouvrions de nouveau notre portail à partir du 20 août 2024.
The Angels Santé fundraising process takes an average of 3 to 6 months from application to closing. Before applying, make sure you can anticipate this timeframe.
Our selection process
Submit your application on our Dealum platform
According to our investment thesis
A one-hour meeting before validation to pitch
/1 to 1.5 month
*210 € participation fee per company
( HR, IP, finance, contracts, négociation …)
1 month
pitch and investment
*4.5% Success fee
Discover our Portfolio Companies
Hephaistos-Pharma is developing a new generation of immunostimulant to treat metastatic and hardly accessible tumors
Alga Therpeutics produces cancer-fighting antibodies from micro-algae.
Abcely develops innovative medical and pharmaceutical technologies for the treatment of mucosal cancers.
A new generation of digital solutions for pain management throughout the patient journey.
Odimma develops personalized immunotherapy using AI and synthetic DNA technology.
